Relationship Between Euglycemic Diabetic Ketoacidosis and SGLT-2 Inhibitors

Global Journal of Endocrinological Metabolism
doi 10.31031/gjem.2018.02.000530
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Crimson Publishers

Related search

SGLT Inhibitors and Euglycaemic Diabetic Ketoacidosis: Earlier Observations Rediscovered

British Journal of Diabetes
2019English

Sodium Glucose Cotransporter-2 (SGLT-2) Inhibitor Related Diabetic Ketoacidosis

European Scientific Journal ESJ
2019English

Euglycemic Diabetic Ketoacidosis Secondary to Dapagliflozin Use: A Case Report

Journal of Emergency Medicine
Emergency Medicine
2018English

Euglycemic Diabetic Ketoacidosis With Prolonged Glucosuria Associated With the Sodium-Glucose Cotransporter-2 Canagliflozin

Journal of Investigative Medicine High Impact Case Reports
RiskEpidemiologyReliabilitySafetySafety ResearchQuality
2017English

Sodium–glucose Co-Transporter 2 Inhibitors: Think Twice About Diabetic Ketoacidosis

2018English

Euglycemic Diabetic Ketoacidosis Secondary to Dapagliflozin in a Patient With Colon Malignancy

Case Reports in Endocrinology
EndocrinologyMetabolismDiabetes
2019English

Euglycemic Diabetic Ketoacidosis in a Young Pregnant Woman Precipitated by Urinary Tract Infection

Cureus
2020English

Euglycemic Diabetic Ketoacidosis Induced by Empagliflozin, Sodium-Glucose Cotransporter-2 Inhibitor, in Patient With Diabetes Mellitus Type 2 After Thoracic Surgery

Lijecnicki Vjesnik
Medicine
2020English

SGLT-2 Inhibitors – Are They to Stay?

Diabesity
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy